HC Wainwright & Co. Maintains Buy on Calumet, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

HC Wainwright & Co. analyst Amit Dayal maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $60 to $75.